Abstract
Membrane-bound pyrophosphatases (mPPases) regulate energy homeostasis in pathogenic protozoan parasites and lack human homologues, which makes them promising targets in e.g. malaria. Yet only few nonphosphorus inhibitors have been reported so far. Here, we explore an isoxazole fragment hit, leading to the discovery of small mPPase inhibitors with 6–10 μM IC50 values in the Thermotoga maritima test system. Promisingly, the compounds retained activity against Plasmodium falciparum mPPase in membranes and inhibited parasite growth.
Highlights
Membrane-bound pyrophosphatases regulate energy homeostasis in pathogenic protozoan parasites and lack human homologues, which makes them promising targets in e.g. malaria
Protozoan diseases such as malaria and leishmaniasis affect many vertebrate species and are a major cause of human mortality or morbidity worldwide.[1,2]. They are caused by protist parasites such as Plasmodium spp., Toxoplasma spp., Trypanosoma spp., and Leishmania spp
Parasitic protists express one or two types of membranebound pyrophosphatases, which are the focus of this study.[10,11] Membrane-bound pyrophosphatases (mPPases) are large (70−81 kDa) homodimeric integral membrane proteins, consisting of 15−17 transmembrane helices per monomer, which hydrolyze pyrophosphate into orthophosphate.[11]
Summary
Johansson − Drug Research Program, Division of Pharmaceutical Chemistry and Technology, Faculty of Pharmacy, University of Helsinki, FI-00014 Helsinki, Finland; orcid.org/0000-0002-8226-4813. Ayman Khattab − Malaria Research Laboratory, Translational Immunology Research Program, Department of Bacteriology and Immunology, Haartman Institute, University of Helsinki, FI-00014 Helsinki, Finland. Seppo Meri − Malaria Research Laboratory, Translational Immunology Research Program, Department of Bacteriology and Immunology, Haartman Institute, University of Helsinki, FI-00014 Helsinki, Finland. Jari Yli-Kauhaluoma − Drug Research Program, Division of Pharmaceutical Chemistry and Technology, Faculty of Pharmacy, University of Helsinki, FI-00014 Helsinki, Finland; orcid.org/0000-0003-0370-7653. Gustav Boije af Gennäs − Drug Research Program, Division of Pharmaceutical Chemistry and Technology, Faculty of Pharmacy, University of Helsinki, FI-00014 Helsinki, Finland pubs.acs.org/acsmedchemlett. The manuscript was written through contributions of all authors. All authors have agreed to the final version of the manuscript
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.